Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Rain Oncology is a operator of a clinical stage biotechnology company.
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases.
ArcherDX is a biotechnology firm specializing in cancer research.
Quellis Biosciences is an emerging biopharmaceutical company focused on discovering best-in-class new molecules.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.
PTx is a biopharmaceutical company committed to the development and commercialization of therapies that improve the treatment of cancer.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.
Xontogeny is a biotech aggregator that seeks to accelerate the development of life science technologies.
Vensun Pharmaceuticals is a pharmaceutical company developing generic prescription products in various dosage forms.
Perceptive Advisors has invested in 226 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Biopharma, Therapeutics. The firm invests across 12 different industry categories.
Among tracked funding rounds, Rain Oncology received $63.0M in a Series B round. Perceptive Advisors's total known invested capital is $30.3B.
Perceptive Advisors's average investment size is $134.2M across its portfolio of 226 companies.
Recent Perceptive Advisors portfolio additions include Rain Oncology, ReViral, Dynacure. These companies were founded in 2020 or later.